Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-12-19
1999-02-23
Knode, Marian
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514249, 514245, 514246, 514248, 514256, 514562, 514563, 514564, 514565, 514185, 514186, 514187, 544257, 544258, 544259, 544260, 544261, A01N 4366, A61K 3153, A61K 31495
Patent
active
058744339
ABSTRACT:
Inhibitor of the use of tetrahydrobiopterin as a cofactor for nitric oxide synthase, e.g., substituted 4-phenyl(hydropyridines) such as 1-methyl-4-(3',4'-dihydroxyphenyl)-1,2,3,6-tetrahydropyridine or, 4-(3',4'-dihydroxyphenyl)-1,2,3,6-tetrahydropyridine) or tetrahydropterin analog which does not replace tetrahydrobiopterin as a substrate for nitric oxide synthase such as (6R,S)-6,7-dimethyl-tetrahydropterin or (6R,S)-tetrahydrofolic acid or 2,4-diamino-, 2,6-diamino, or 4,6-diamino mono- or disubstituted pyrimidines or the corresponding pyrimidine-3-oxides such as 2,4-diamino-6-(diethylamino)pyrimidine, 2,4-diamino-6-piperidino-pyrimidine-3-oxide, 2,4-diamino-6-hydroxypyrimidine, 4,6-diamino-2-hydroxypyrimidine or 2,5-diamino-4,6-dihydroxypyrimidine is administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylaxis or treatment of cytokine- or endotoxin-induced hypotension (e.g., septic shock). The latter two types are advantageously administered with nitric oxide synthase inhibitors (concurrent therapy) or to potentiate the effect of .alpha..sub.1 -adrenergic agonists in the prophylaxis or treatment of induced hypotension.
REFERENCES:
patent: 3382247 (1968-05-01), Anthony
patent: 3557106 (1971-01-01), Roch
patent: 3644364 (1972-02-01), Anthony
patent: 4670438 (1987-06-01), Austel et al.
patent: 4701455 (1987-10-01), Nichol et al.
patent: 5002944 (1991-03-01), Spada et al.
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5059712 (1991-10-01), Griffith
patent: 5132453 (1992-07-01), Griffith
patent: 5158883 (1992-10-01), Griffith
patent: 5196195 (1993-03-01), Griffith
patent: 5216025 (1993-06-01), Gross et al.
patent: 5273875 (1993-12-01), Griffith
patent: 5281627 (1994-01-01), Griffith
patent: 5298506 (1994-03-01), Stamler et al.
patent: 5401844 (1995-03-01), Ayling et al.
patent: 5449668 (1995-09-01), Wahl et al.
Ponzone et al. "catalytic activity of tetrahydrobiopterin in dihydropterine reductase defiency and indications for treatment". Pediatric Research. vol. 33, No. 2, pp. 125-128, 1993.
Gross, S.S.,et al,Biochem.Biophys.Res.Commun,178,No. 3,823-829 (Aug. 15, 1991).
Kaufman,S,et al, J.Biol.Chem.,234,No. 10,2683-2688(Oct. 1959).
Kaufman,S.,et al, J.Biol.Chem.,242,No. 17,3934-3943(Sep. 1967).
Kerler,F.,et al, Exp.Cell Res.,189,151-156(1990).
Kwon,N.S.,et al,J.Biol.Chem.,264,No. 34,20496-20501(Dec. 1989).
Milstien,S.,et al,Biochem.Biophys.Res.Commun.,128,No. 3,1099-1107(May 1985).
Nichol,C.,et al, Ann.Rev.Biochem.54,729-764(1985).
Tayeh,M.A., et al.J.Biol.Chem.,264,No. 33,19654-19658(1989).
Werner-Felmayer,G.,et al. J.Exp.Med.,172,1599-1607(1990).
Ziegler,I.,et al, J.Biol.Chem.,265,No. 28,17026-17030(Oct. 1990).
Marletta, M.A., "Nitric oxide: biosynthesis and biological significance," name of publication unknown, Elsevier Science Publishers, Ltd. (UK), pp. 448-453 (1989).
Book of Abstracts, Second International Meeting Biology of Nitric Oxide, cover page, meeting schedule page, abstract headed Oct. 1991.
Synthesis of Tetrahydrobiopterin is a Requirement for Induction of Nitric Oxide Synthesis by LPS/Interferon in Vascular Smooth Muscle (Steven S. Gross and Roberto Levi).
Werner, E., et al, Biochem. J., 262:861-866(1989).
Moncada, S., et al, Pharmacological Reviews 43(2):109-142 (1991).
Gross, S.S., et al, Biochem. Biophys. Res. Commun. 170, 96-103 (Jul. 1990).
Gross, S.S., et al, J. Biol. Chem. 267, 25722-25729 (Dec. 1992).
Kilbourn, R.G., et al, Biochem. Biophys. Res. Commun. 172, 1132-1138 (Nov. 1990).
Kilbourn, R.G., et al, J. Natl. Cancer Inst. 84, 827-831 (Jun. 1992).
Collier, Jr., et al, Trends in Pharmacological Sciences Including Toxicological Sciences, Elsevier Science Publishers, Ltd., published in UK 1989, frontpage and pages 428-431.
Kilbourn, R.G., et al, Proc. Natl. Acad. Sci. U.S.A, 87, 3629-3632, 1990.
McCall, J.M., et al, J. Org. Chem., 40, No. 22, 3304-3306, 1975.
Rees, D.D., et al, Br. J. Pharmacol., 96, 418-424 (1989).
Rees, D.D., et al, Nitric oxide from L-arginine: a bioregulatory system, S. Moncada et al eds., Elsevier Science Publishers, BV, 485-487 (1990).
Gessner, W., et al, J. Med. Chem., 28, 311-317 (1985).
Vallance, P., et al, New Horizons, 77-86 (Feb. 1993).
Rees, D.D., et al, Br. J. Pharmacol., 101, 746-752 (1992).
Stuehr, D.J., et al, Advances in Enzymology 65, 287-346 (1992).
Gross, S., et al, FASEB Journal 6, A1509, 1992.
Gross, S., J. Vasc. Res., 29, 125-126, Abstract 147, 1992.
Gray, G.A., et al, Br. J. Pharmacol., 103, 1218-1224 (May 1991).
Aisaka, K., et al, Biochem. Biophys. Res. Commun. 163, No. 2, 710-717 (Sep. 15, 1989).
Julou-Schaeffer, G., et al, Am. J. Physiol. 259, H10-38-H1043, Oct. 1990.
Giovanelli, J., et al, Medline Abstract of Proc. Nat'l. Acad. Sci. USA 88(16), 7091-7095 (Aug. 1991).
Abell, C.W., et al., Science, vol. 224, 405-407, Apr. 1984.
Craine, J. E., et al., J. Biol. Chem, vol. 247, No. 19, 6082-6091 (1972).
Cornell Research Foundation Inc.
Knode Marian
Lee Datquan
LandOfFree
Blocking utilization of tetrahydrobiopterin to block induction o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blocking utilization of tetrahydrobiopterin to block induction o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blocking utilization of tetrahydrobiopterin to block induction o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-307234